Repro Med Systems, Inc. (KRMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
KRMD Stock Summary
- KRMD's price/sales ratio is 6.6; that's higher than the P/S ratio of 82.47% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.25 for KORU MEDICAL SYSTEMS INC; that's greater than it is for merely 15.67% of US stocks.
- With a year-over-year growth in debt of 528.52%, KORU MEDICAL SYSTEMS INC's debt growth rate surpasses 96.57% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to KORU MEDICAL SYSTEMS INC are KTOS, VCYT, EKSO, FTFT, and UDMY.
- KRMD's SEC filings can be seen here. And to visit KORU MEDICAL SYSTEMS INC's official web site, go to www.korumedical.com.
KRMD Valuation Summary
- KRMD's price/sales ratio is 6.5; this is 217.07% higher than that of the median Healthcare stock.
- KRMD's price/sales ratio has moved up 6.2 over the prior 243 months.
Below are key valuation metrics over time for KRMD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
KRMD | 2023-01-20 | 6.5 | 5.4 | -22.7 | -16.9 |
KRMD | 2023-01-19 | 6.5 | 5.4 | -22.8 | -17.0 |
KRMD | 2023-01-18 | 6.4 | 5.4 | -22.5 | -16.7 |
KRMD | 2023-01-17 | 6.5 | 5.4 | -22.8 | -17.0 |
KRMD | 2023-01-13 | 6.0 | 5.0 | -21.0 | -15.6 |
KRMD | 2023-01-12 | 6.7 | 5.6 | -23.5 | -17.6 |
KRMD Growth Metrics
- Its 5 year net cashflow from operations growth rate is now at 558.09%.
- The 4 year cash and equivalents growth rate now stands at 107.73%.
- Its 4 year net cashflow from operations growth rate is now at 558.09%.

The table below shows KRMD's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 27.04186 | -7.458145 | -7.752773 |
2022-06-30 | 25.32201 | -6.168674 | -7.620991 |
2022-03-31 | 24.30355 | -3.465929 | -5.824199 |
2021-12-31 | 23.49018 | -4.31951 | -4.562823 |
2021-09-30 | 21.05689 | -5.314138 | -4.329093 |
2021-06-30 | 21.09666 | -6.227022 | -2.98614 |
KRMD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- KRMD has a Quality Grade of D, ranking ahead of 19.43% of graded US stocks.
- KRMD's asset turnover comes in at 0.501 -- ranking 94th of 186 Medical Equipment stocks.
- CSII, NVRO, and XENT are the stocks whose asset turnover ratios are most correlated with KRMD.
The table below shows KRMD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.501 | 0.601 | -0.483 |
2021-03-31 | 0.531 | 0.618 | -0.535 |
2020-12-31 | 0.646 | 0.618 | -0.188 |
2020-09-30 | 0.852 | 0.630 | -0.036 |
2020-06-30 | 1.170 | 0.634 | 0.047 |
2020-03-31 | 1.753 | 0.636 | 0.245 |
KRMD Price Target
For more insight on analysts targets of KRMD, see our KRMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $5.17 | Average Broker Recommendation | 1.83 (Hold) |
KRMD Stock Price Chart Interactive Chart >
KRMD Price/Volume Stats
Current price | $3.91 | 52-week high | $4.18 |
Prev. close | $3.94 | 52-week low | $1.82 |
Day low | $3.72 | Volume | 80,900 |
Day high | $3.99 | Avg. volume | 50,528 |
50-day MA | $3.40 | Dividend yield | N/A |
200-day MA | $2.66 | Market Cap | 177.04M |
Repro Med Systems, Inc. (KRMD) Company Bio
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.
Latest KRMD News From Around the Web
Below are the latest news stories about KORU MEDICAL SYSTEMS INC that investors may wish to consider to help them evaluate KRMD as an investment opportunity.
KORU Medical Systems to Participate in the Piper Sandler 34th Annual Healthcare ConferenceMAHWAH, N.J., November 21, 2022--KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference on December 1st, 2022. |
KORU Medical Systems to Participate in Upcoming Investor ConferencesMAHWAH, N.J., November 10, 2022--KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will participate in two upcoming investor conferences. |
KORU Medical Systems Announces 2022 Third Quarter Financial ResultsMAHWAH, N.J., November 09, 2022--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today reported financial results for the third quarter ended September 30, 2022. |
KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira PharmaceuticalsMAHWAH, N.J., November 08, 2022--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced the progression of its agreement with Kira Pharmaceuticals, including expansion into three important additional indications. |
KORU Medical Systems to Report Third Quarter 2022 Financial Results on November 9, 2022MAHWAH, N.J., October 26, 2022--KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report third quarter 2022 financial results on Wednesday, November 9, 2022. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. |
KRMD Price Returns
1-mo | 15.00% |
3-mo | 63.60% |
6-mo | 53.94% |
1-year | 41.67% |
3-year | -35.90% |
5-year | 279.61% |
YTD | 9.52% |
2022 | 19.00% |
2021 | -50.17% |
2020 | -7.81% |
2019 | 295.76% |
2018 | 32.00% |
Loading social stream, please wait...